Incyte Corp at Evercore ISI HealthCONx Virtual Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : From the feedback that you've gotten so far, who have kind of been the early adopters of Opzelura so far on both on the physician side as well as on the patient side, the initial group of patients trying the drug?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : You mentioned a good number of patients switching from topical steroids. As you think about getting broad reimbursement and what payers might want before a patient is allowed to try Opzelura once some of those wheels are in place, do you think the primary population will be people who have tried topical steroids? Or do you think there is likely to be also some requirements to kind of have tried a topical calcineurin inhibitor for some of these patients?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Got it. On your last earnings call, you talked about some texture considerations that have come up in the commercial setting, some grittiness that a few patients had seen. Maybe we can get just an updated sense for how you're thinking about that, how broad it's been in the commercial landscape, and just any thoughts on what might be causing some of those considerations.

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Any latest thinking just on how long that root cause analysis might take? And also if you've kind of screened the other batches to be certain that you're not seeing anything in those?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Got it. On the reimbursement trajectory, I think gross to net right now is high, but you kind of talked about that coming down meaningfully over time. What's kind of the trajectory that we should be thinking about for that in 2022 and beyond for that group to net -- to start decreasing?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Got it. With vitiligo coming on board on next year as well, I guess just based on what you're seeing in atopic derm so far with the Opzelura launch as well as some of the feedback from docs, how are you thinking about the relative vitiligo opportunity versus atopic derm now?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Got it. That makes sense. Maybe shifting gears to some of the other moving parts. Just on the LIMBER program for Jakafi. We've got a few updates coming up. Maybe you can just help kind of set the stage for what we should be looking for in each of those. And ultimately, what percent of the population for MS you think would switch to one of the LIMBER approaches?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Got it. Last question for me since I think we're already a minute over, just tell us how you think about building out the pipeline on -- where are you kind of focused both in terms of internal R&D as well as potential for external types of deals as well?

Question: Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst : Awesome. I think that's all we've got time for. But thank you, Christiana, Steven and Christine for joining us. And thanks, everyone, for listening as well.